A Minimally-Invasive Sponge on a String Device for Screening for Barrett's Esophagus

Inclusion Criteria:

Subjects with known Barrett's Esophagus (BE).

* Patients with a BE segment ≥ 1cm in maximal extent endoscopically.
* Histology showing evidence of intestinal metaplasia with or without presence of dysplasia.
* Undergoing clinically indicated endoscopy. Subjects without known evidence of BE - Undergoing clinically indicated diagnostic endoscopy

Exclusion Criteria:

* Subjects with known BE.

  * Patients with prior history of ablation (photodynamic therapy, radiofrequency ablation, cryotherapy, argon plasma coagulation). Patients with history of endoscopic mucosal resection alone will not be excluded.
  * Patients with history of esophageal resection for esophageal carcinoma. Subjects with or without known evidence of BE (on history or review of medical records).
  * Pregnant or lactating females.
  * Patients who are unable to consent.
  * Patients with current history of eosinophilic esophagitis, achalasia or uninvestigated dysphagia.
  * Patients on oral anticoagulation including Coumadin, Warfarin.
  * Patients on antiplatelet agents including Clopidogrel, unless discontinued for 3 days prior to the sponge procedure.
  * Patients on oral thrombin inhibitors including Dabigatran and oral factor X a inhibitors such as rivaroxaban, apixaban and edoxaban, unless discontinued for 3 days prior to the sponge procedure.
  * Patients with history of known varices or cirrhosis.
  * Patients with history of esophageal resection for esophageal carcinoma.
  * Patients with congenital or acquired bleeding diatheses.
  * Patients with a history of esophageal squamous dysplasia.
  * Patient has known carcinoma of the foregut (pancreatic, bile duct, ampullary, stomach, or duodenum) within 5 years prior to study enrollment.